Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan in transplant-associated thrombotic microangiopathy
NCT05148299Phase 2Completed
- Sponsor
- Sobi
- Start
- Feb 2022
- Primary completion
- Dec 2024
- Modality
- PEGylated Peptides
- Countries
- 5
01
Overview
A Phase 2 trial of pegcetacoplan in transplant-associated thrombotic microangiopathy (TA-TMA), sponsored by Sobi. Started Feb 2022; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
transplant-associated thrombotic microangiopathy (TA-TMA)
Beyond the preview
Go deeper on NCT05148299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05148299.